NextCell Pharma publishes interim report for the first quarter of 2026
Operating revenues were SEK 2.8 million, the result was SEK -10.4 million, and the company carried out a directed share issue of SEK 15 million.
See the latest news and media coverage for NextCell. We track all announcements, press releases, and industry mentions in real time, all in one place.
Swedish stem cell biotechnology company
nextcellpharma.comLast updated
In short: NextCell Pharma secured 15 million SEK in new funding, launched a global research platform with Fujifilm, and reported long-term ProTrans trial data.
Operating revenues were SEK 2.8 million, the result was SEK -10.4 million, and the company carried out a directed share issue of SEK 15 million.
The board was re-elected, two incentive programs were introduced and the CEO presented a new brand strategy.
The product is a standardized MSC solution for research, available globally via FUJIFILM. It combines NextCell's cells with optimized culture medium.
The annual report for the fiscal year 1 September 2024–31 December 2025 is available as an attachment or on the company's website. The share is traded on Nasdaq First North Growth Market under the short name NXTCL.
Get an in-depth profile of NextCell Pharma AB, including a general overview of the company's business and key management, as well as employee data and...
Collaboration results in platform to help researchers overcome challenges in MSC research...
FUJIFILM Biosciences, a global leader in the life science market, and NextCell Pharma AB, a clinical-stage company specializing in cell therapy using umbilical cord mesenchymal...
Redeye’s analyst just published a Research Update on NextCell Pharma.Click here to read the articleMake sure to add NextCell Pharma to your Watchlist at Redeye...
Track NextCell and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.